Cell migration inducing protein alleviates adverse cardiac remodelling after ischaemia and reperfusion injury by controlling fibroblast activation
Cardiovascular Research · 26.06.2026 · 122 (9) · 1243-1256
DOI: 10.1093/cvr/cvag086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 22.04.2026. Verfasst von Rebekka Schneckmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Pharmacology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Universitätsstr. 1, 40225 Düsse…. Hauptthemen laut MEDLINE: Ventricular Remodeling, Myocardial Reperfusion Injury, Myocardial Infarction, Myocardium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: German Research Foundation.
Abstract (Originalsprache)
Aims
Myocardial infarction (MI) remains one of the leading causes of mortality and morbidity worldwide. Cardiac remodelling is a key process following MI, involving changes in cellular composition and extracellular matrix (ECM) to adapt to injury. However, maladaptive remodelling can worsen cardiac function, leading to cardiac fibrosis and heart failure. In the context of MI, cell migration inducing protein (CEMIP) has come into focus and its ability to modulate hyaluronan (HA) turnover has raised critical questions about its role in post-MI healing. Methods and results This study investigates the role of global CEMIP deletion in a murine closed chest ischaemia and reperfusion injury (I/R) model. We demonstrate that Cemip is significantly upregulated in the infarcted area of the heart peaking at 72 h post-I/R. Furthermore, global deletion of Cemip resulted in significantly impaired cardiac function post-I/R accompanied by an increased scar size, cardiac collagen content, and PERIOSTIN deposition. Flow cytometric analyses revealed increased cardiac fibroblast abundance driven by a decrease in apoptosis at 72 h post-I/R. In contrast, cardiac fibroblast proliferation was strongly inhibited in Cemip-KO fibroblasts. Upregulation of myofibroblast-associated genes as well as morphological changes in Cemip-KO cardiac fibroblasts pointed towards a crucial role of CEMIP in controlling fibroblast to myofibroblast conversion. Single-cell RNA sequencing of infarcted hearts confirmed upregulation of pro-fibrotic genes in Cemip-KO myofibroblasts. Mechanistically, Cemip-deficiency appears to maintain TGF-β activity in cardiac fibroblasts by enhancing integrin-mediated latent TGF-β activation and constitutive SMAD3 activation. This might foster a pro-fibrotic gene expression programme leading to improved fibroblast survival, aberrant activation and myofibroblast persistence post-I/R.
Conclusion
Our data suggest that CEMIP contributes to post-infarct healing by limiting excessive activation and fibroblast to myofibroblast differentiation during scar formation. Thus, CEMIP may be considered as a novel target to prevent maladaptive cardiac fibrosis and heart failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Pharmacology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Germany.
- Core Unit Bioinformatics, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany.
- Genomics & Transcriptomics Laboratory (GTL), Biological and Medical Research Center (BMFZ), Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany.
ORCID-Profile: Rebekka Schneckmann, Theresa Hube, Viktoria Darakchieva, Aria Zardkouhi, Mirela Balan, Tobias Lautwein, Simone Gorreßen, Daniel J Gorski, Katharina Bottermann
Förderung
- German Research Foundation
Zitieren
APA
Schneckmann, R., Hube, T., Darakchieva, V., Zardkouhi, A., Balan, M., Lautwein, T., Petz, A., Gorreßen, S., Gorski, D. J., Bottermann, K., & Fischer, J. W. (2026). Cell migration inducing protein alleviates adverse cardiac remodelling after ischaemia and reperfusion injury by controlling fibroblast activation. Cardiovascular Research, 122(9), 1243-1256. https://doi.org/10.1093/cvr/cvag086
Vancouver
Schneckmann R, Hube T, Darakchieva V, Zardkouhi A, Balan M, Lautwein T, et al. Cell migration inducing protein alleviates adverse cardiac remodelling after ischaemia and reperfusion injury by controlling fibroblast activation. Cardiovascular Research. 2026;122(9):1243-1256. doi:10.1093/cvr/cvag086
BibTeX
@article{Schneckmann2026,
author = {Schneckmann, Rebekka and Hube, Theresa and Darakchieva, Viktoria and Zardkouhi, Aria and Balan, Mirela and Lautwein, Tobias and Petz, Anne and Gorreßen, Simone and Gorski, Daniel J and Bottermann, Katharina and Fischer, Jens W},
title = {Cell migration inducing protein alleviates adverse cardiac remodelling after ischaemia and reperfusion injury by controlling fibroblast activation},
journal = {Cardiovascular Research},
year = {2026},
volume = {122},
number = {9},
pages = {1243--1256},
doi = {10.1093/cvr/cvag086}
}
EUVIMED